ArticleBioinformation2026
Low T3 syndrome and short-term outcomes in patients with acute decompensated heart failure: A retrospective observational study.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute decompensated heart failure (ADHF) drives frequent hospitalizations with high short-term morbidity/mortality, yet low triiodothyronine (T3) syndrome characterized by unexplained low serum free T3 remains understudied as a prognostic marker in resource- limited ADHF settings. Therefore, it is of interest to assess the prevalence of low T3 and its association with in-hospital mortality, length of stay and 30-day readmission in 115 ADHF patients. Low T3 syndrome affected 40.9% (47/115) of patients, who exhibited higher in- hospital mortality (25.5% versus 7.4%, p=0.006), longer stays (9.8±3.6 versus 6.9±2.4 days) and greater 30-day readmissions (34.3% versus 15.9%) than normal T3 controls. Multivariate analysis confirmed that low T3 was an independent predictor of mortality (adjusted OR 3.42, 95% CI 1.28-9.15, p=0.014) after adjusting for age, ejection fraction and creatinine. Thus, we show low T3 syndrome as a prevalent, actionable prognostic biomarker for risk stratification and targeted intervention in resource-constrained ADHF management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.